TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT05907980: A Phase Ia/Ib Open-label, Dose-escalation Study to Evaluate the Safety and Pharmacokinetics of ROSE12 as a Single Agent and in Combination With Other Anti-tumor Agents in Patients With Locally Advanced or Metastatic Soli

Sponsor: Chugai Pharmaceutical · Phase: PHASE1 · Area: ONCOLOGY · Target Enrollment: 209 pts

Competing Trials Overlap

4 Active Trials

Excess Burn Exposure

$3,675,672

Rescue Site Savings

+$2,419,032

Unlock Full NCT05907980 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT05907980 Rescue Dossier →